Compare Centrus Energy Corp (LEU) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centrus Energy Corp vs Eli Lilly And Co — how do they compare? Centrus Energy Corp trades at $142.02 (market cap $2.91B), while Eli Lilly And Co trades at $1,178.99 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 357.4× Centrus Energy Corp's market cap, and Eli Lilly And Co pays a 0.59% dividend while Centrus Energy Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Centrus Energy Corp for 29 Days and Eli Lilly And Co for 93 Days on average.
| LEU | LLY | |
|---|---|---|
Market Cap | $2.91B | $1.04T |
Volume | 903,777 | 3,064,878 |
Sector | Energy | Health |
52-Week High | $436.00 | $1.28K |
52-Week Low | $138.18 | $799.57 |
Typical Hold Time | 29 Days | 93 Days |
Enterprise Value | $2.22B | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $143.88, down 2.22% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows elevated valuation metrics (P/E 75.18) but maintains profitability with 10.23% net margins. Recent news highlights Centrus' strategic position as the only US-licensed HALEU producer, benefiting from nuclear energy growth and Russian uranium import bans.
The investment case balances high growth potential in nuclear fuel supply against execution risks and premium valuation. Analyst consensus at $218.10 suggests 52% upside, but technical indicators and recent equity dilution from a $500 million offering present near-term headwinds. Success depends on contract execution and nuclear industry adoption timelines.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
